News

#myEUspace competition by EUSPA

Published on | 4 years ago

Programmes Digital, Industry & Space

The European Union Agency for the Space Programme (EUSPA) announced a new competition that targets innovators and entrepreneurs ready to develop and commercialise innovative solutions that leverage EU space data and services.

The objective of the competition is to support the development of innovative commercial solutions - such as mobile apps or hardware-based solutions, for example wearables, asset management and tracking solutions, robotics etc. - that are leveraging EU Space data from Galileo and/or Copernicus.

#myEUspace competition is part of the European Commission Casssini initiative and consists of 2 independent and parallel tracks:

  • Track 1 – From Idea to Prototype/customer validation.
  • Track 2 – From Prototype to Product /Market entry.

Application deadline: 15th November 2021 (23:59 CET).

More information can be found on the EUSPA website

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1785 articles available search in articles 

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.